A Study of Cardio Pulmonary Manifestations in Systemic Sclerosis by Mathew, Joseph
  
A STUDY OF CARDIO PULMONARY 
MANIFESTATIONS IN SYSTEMIC 
SCLEROSIS 
 
                            DISSERTATION SUBMITTED FOR  
     MD DEGREE (BRANCH 1) GENERAL MEDICINE  
APRIL 2012 
 
 
 
 
 
 
 
 
 
 
THE TAMILNADU  
DR. M.G.R MEDICAL UNIVERSITY 
CHENNAI 
  
CERTIFICATE 
This is to certify that the dissertation entitled “A STUDY OF 
CARDIO PULMONARY MANIFESTATIONS IN SYSTEMIC 
SCLEROSIS” is the bonafide work of Dr. MATHEW JOSEPH, in 
partial fulfillment of the university regulations of the Tamil Nadu  Dr. 
M.G.R. Medical University, Chennai, for M.D General Medicine  
Branch I examination to be held in April 2012. 
                                                                                    
                                                                       
Dr. Moses.K.Daniel M.D                       Dr. S Vadivelmurugan M.D 
Professor and HOD,                             Professor,                                                                                      
Department of General Medicine,     Department of General Medicine, 
Government Rajaji Hospital,     Government Rajaji Hospital, 
Madurai Medical College,                       Madurai Medical College, 
Madurai.        Madurai. 
 
 
 
 
  
DECLARATION 
       I, Dr. MATHEW JOSEPH, solemnly declare that, I carried          
out this dissertation “A STUDY OF CARDIO PULMONARY 
MANIFESTATIONS IN SYSTEMIC SCLEROSIS” is a bonafide 
record of work done by me at the Department of General Medicine, Govt. 
Rajaji Hospital, Madurai, under the guidance of Dr. S Vadivelmurugan 
M.D, Professor of Medicine, Department of General Medicine, Madurai 
Medical College, Madurai.   
        This dissertation is submitted to The Tamil Nadu Dr. M. G. R. 
Medical University, Chennai in partial fulfillment of the rules and 
regulations for the award of M.D Degree General Medicine Branch-I 
examination to be held in April 2012. 
 
Place: Madurai                                                                                                  
Date:                                                                Dr. MATHEW JOSEPH 
 
 
 ACKNOWLEDGEMENT 
         At the outset, I thank our Dean Dr. Edwin Joe M.D, for permitting 
me to use the facilities of Madurai Medical College and Government 
Rajaji Hospital to conduct this study. 
        I wish to express my respect and sincere gratitude to my beloved 
teacher and Head of Department of Medicine PROF.MOSES K 
DANIEL M.D for his valuable guidance and encouragement throughout 
the study and also during my post graduate course. I owe my sincere 
thanks to him. 
       I also owe my sincere thanks to my beloved unit chief and my guide 
PROF.S.VADIVELMURUGAN, M.D., for his guidance and support 
throughout the conduct of the study. 
        I express my special thanks to HOD of Department of Thoracic 
medicine Dr. C Ramesh M.D(chest), D.T.C.D; HOD of Department of 
Cardiology Dr. R A Janarthanan M.D,D.M(CARDIOLOGY) and Asst 
Professor Dr. Arulrajamurugan. MD, DM (RHEUMATOLOGY) for 
their excellent guidance throughout the study. 
       Knowledge and kindness abounds my beloved teachers, Dr. 
V.T.Premkumar.M.D., Dr. Balajinathan M.D, Dr.Natarajan.M.D.,        
 Dr. Bagialakshmi M.D, Dr. Sangumani.M.D., and Dr. C. Dharmaraj. 
M.D., I owe them a lot and sincerely thank them. 
         I offer my heartfelt thanks to the Assistant Professors of my unit 
Dr.Sheela Ganesh MD., Dr.A.Senthamarai MD., and Dr.Ganesh 
Babu MD for their constant encouragement, timely help and critical 
suggestions throughout the study and also for making my stay in the Unit 
both informative and pleasurable. 
        I profusely thank the Department of Radiology, Department of 
Cardiology, Department of Dermatology and Department of Thoracic 
Medicine for their cooperation and support. 
        My patients, who form the most integral part of my work, were 
always kind and cooperative. I cannot but pray for their speedy recovery 
and place this study as a tribute to them and to numerous others likely 
affected.  
       My family and friends especially Dr. Sreeraj , Dr. Nishad and Dr. 
Jaisankar have stood by me during my times of need. Their help and 
support have been invaluable to the study. 
        Above all I thank the Lord Almighty for His kindness and 
benevolence. 
 CONTENTS 
 
 S.No.    Title Page       Page No. 
1.  INTRODUCTION      1 
2.  REVIEW OF LITERATURE     2 
3.  AIM OF THE STUDY      36 
4.  MATERIALS AND METHOD    37 
5.  OBSERVATIONS AND RESULTS    41  
6.  DISCUSSION       64 
7.  CONCLUSIONS       72 
8.  LIMITATIONS OF THE STUDY    73 
9.  SUMMARY       74 
  APPENDIX 
   GLOSSARY 
BIBLIOGRAPHY 
PROFORMA   
MASTER CHART 
ETHICAL COMMITTEE CLEARANCE FORM 
 
 
 INTRODUCTION 
 Scleroderma, or systemic sclerosis (SSc), is a chronic multisystem 
autoimmune disease characterized by a vasculopathy, diffuse fibrosis of 
skin and various internal organs, and immune abnormalities. The clinical 
manifestations of this disease are extremely heterogeneous and depend on 
the presence and degree of various internal organ involvements. It is a 
profoundly disabling autoimmune disease. The distinguishing pathologic 
hallmark of SSc is the combination of widespread capillary loss and 
obliterative vasculopathy of small arteries and arterioles, together with 
fibrosis in the skin and internal organs. Fibrosis affecting multiple organs 
distinguishes SSc from other connective tissue diseases. Fibrosis is found 
in the skin, lungs, gastrointestinal tract, heart, tendon sheath, 
perifascicular tissue surrounding skeletal muscle, and some endocrine 
organs. Obliterative vasculopathy as a late finding is prominent in the 
heart, lungs, kidneys, and intestinal tract. Virtually every organ is 
affected in SSc. In the previous era scleroderma renal crisis was the most 
common cause of mortality in these patients. After the advent of ACE 
inhibitors mortality due to this complication came down. Now the 
pulmonary and cardiac involvement of scleroderma is the leading cause 
of death and is present in almost all patients with systemic sclerosis.There 
is a vast variety of cardiopulmonary involvement in systemic sclerosis. 
    REVIEW OF LITERATURE 
HISTORICAL REVIEW 
Cases of skin disease similar to scleroderma may be found in the 
writings of Hippocrates as far back as 460–370 B.C. Other ancient 
physicians, including Oribasius (325–403 A.D.) and Paulus Agineta 
(625–690 A.D.), also wrote on the subject (42). The first detailed 
description of a scleroderma-like disease was published by Carlo Curzio 
in Naples in 1753(4). The patient, a young woman suffered from 
excessive tension and hardness of the skin. Nearly 100 years later, in 
1847 Élie  Gintrac introduced the term scleroderma, as the skin was the 
most obvious organ involved(1,5).   The word "scleroderma" comes from 
two Greek words: "sclero" meaning hard, and "derma" meaning skin(43). 
The extensive involvement of internal organs has only been realized in 
the second half of the 20th century (6,7,8). 
DEFINITION 
Systemic sclerosis (SSc) is a connective tissue disorder of 
unknown etiology, with heterogeneous clinical manifestations, and 
chronic and often progressive course, which affects the connective tissue 
of the skin, internal organs and the walls of blood vessels(2,3). It is 
 characterized by alterations of the microvasculature, disturbances of the 
immune system and by massive deposition of collagen.  
CRITERIA 
The American College of Rheumatology (former American 
Rheumatism Association - ARA) has defined criteria, that are 97 % 
sensitive and 98 % specific for SSc as follows (10). 
Major criterion:  Proximal diffuse (truncal) sclerosis (skin tightness, 
thickening, non-pitting induration) 
Minor criteria:  
1. Sclerodactyly (only fingers and/or toes) 
2. Digital pitting scars or loss of substance of the digital finger pads.  
3. Bibasilar pulmonary fibrosis 
The patient should fulfill the major criterion or two of the three 
minor criteria. 
CLASSIFICATION 
 The most accepted and widely used classification is proposed by 
Le Roy et al and according to them the disease is classified as follows  
 
 
 SSc subsets according to LeRoy at al (11). 
1. Limited Cutaneous SSc 
Features  
 Raynaud's phenomenon for years at presentation 
 Skin sclerosis limited to hands, feet, face, and forearms, or absent 
 Significant late incidence of pulmonary hypertension, trigeminal 
neuralgia, calcinosis, and teleangiectasia 
 Dilated nailfold capillary loops, usually without capillary dropouts 
detected by widefield nailfold capillaroscopy. 
2. Diffuse cutaneous SSc 
Features 
 Onset of Raynaud's phenomenon within 1 year of onset of skin changes 
 Truncal and acral skin involvement 
 Presence of tendon friction rubs 
 Early and significant incidence of interstitial lung disease, oliguric renal 
failure, diffuse gastrointestinal disease, and myocardial involvement 
 Presence of anti-DNA topoisomerase I (anti-Scl-70) antibodies 
 Absence of anticentromere antibodies 
 Nailfold capillary dilatation and destruction detected by widefield 
nailfold capillaroscopy 
  
EPIDEMIOLOGY 
SSc is an acquired sporadic disease with a worldwide distribution 
and affecting all races. Compared with other connective tissue diseases 
SSc is relatively rare. The incidence is estimated at 9–19 cases per 
million per year. Age, gender, and ethnicity are important factors 
determining disease susceptibility. SSc shows a female predominance 
that is most pronounced in the childbearing years and declines after 
menopause. The overall female/male ratio was reported as 4:1(12,13).  
The most common age of onset for both limited and diffuse cutaneous 
forms is in the range of 30–50 years.  
GENETICS  
SSc shows a non-Mendelian pattern of inheritance. 1.6% of SSc 
patients have a first-degree relative with SSc, a prevalence rate 
substantially higher than in the general population. Genetic investigations 
in SSc have focused on candidate gene polymorphisms. The genes 
encoding angiotensin-converting enzyme (ACE); endothelin-1 and nitric 
oxide synthase; B cell markers (CD19); chemokines (monocyte 
chemoattractant protein-1) and chemokine receptors; interferon signaling 
mediators STAT4 and IRF5; migration inhibitory factor; cytokines 
 [interleukin 1 (IL-1, IL-4, and tumor necrosis factor α (TNF-α)]; growth 
factors and their receptors [connective tissue growth factor (CTGF) and 
transforming growth factor β (TGF-β)]; and extracellular matrix proteins 
[fibronectin, fibrillin, and secreted protein acidic-rich in cysteine 
(SPARC)] have demonstrated association with the development of 
systemic sclerosis.  
PATHOGENESIS 
The three cardinal features of the disease are (1) vasculopathy, (2) 
cellular and humoral auto immunity, and (3) progressive visceral and 
vascular fibrosis in multiple organs. 
 
 Microangiopathy 
Vascular involvement in SSc is extensive, involves multiple 
vascular beds, and has important clinical consequences. Raynaud's 
phenomenon, an early manifestation, is characterized by an altered blood-
flow response to cold challenge. This initially reversible functional 
vascular abnormality is associated with alterations in the autonomic and 
peripheral nervous systems, with impaired production of neuropeptides 
such as calcitonin gene-related peptide from sensory afferent nerves and 
heightened sensitivity of α-2-adrenergic receptors on vascular smooth-
muscle cells.  Raynaud's phenomenon, increased vascular wall thickness, 
vascular occlusion, devascularization, and thickening of the basement 
membrane are features which were described many years ago. Changes in 
the nailfold capillaries are one of the first signs in SSc.(14,15) 
Furthermore, vascular injury is the basis for the major clinical 
manifestations of SSc including pulmonary hypertension, myocardial 
dysfunction and renal involvement. In internal organs, in particular the 
kidney, arterioles are characterized by intimal proliferation, thinning of 
the media, and fibrosis of the adventitia, and exhibit accumulation of 
proteoglycans and collagens(16), probably produced by myofibroblasts . 
In addition, the vascular pathology is associated with altered vascular 
 function, with increased vasospasm, reduced vasodilatory capacity, and 
increased adhesiveness of the blood vessels to platelets and lymphocytes. 
Inflammation and Cellular Immunity 
In the early stages of SSc, activated T cells and 
monocytes/macrophages accumulate in lesional skin, lungs, and other 
affected organs. Infiltrating T cells express CD45 and HLA-DR 
activation markers and display restricted T cell receptor signatures 
indicative of oligoclonal expansion in response to (unknown) antigen.  
Humoral Autoimmunity 
Antinuclear antibodies occur in virtually all patients with SSc. A 
number of mutually exclusive autoantibodies that is highly specific for 
SSc have been described. These antibodies show strong association with 
specific disease phenotypes. Autoantibody levels correlate with disease 
severity, and titers fluctuate with disease activity. While some SSc-
specific autoantibodies are antinuclear and directed against intracellular 
proteins such as topoisomerase-I, and the RNA polymerases, others are 
directed against cell-surface antigens or secreted proteins. 
  
 
 
 Autoantibodies and Associated Features in Systemic Sclerosis (Ssc) 
Target Antigen SSc 
Subset 
Characteristic Clinical Association 
Topoisomerase-I dcSSc Tendon friction rubs, ILD, cardiac 
involvement, scleroderma renal 
crisis 
Centromere proteins lcSSc Digital ischemia, calcinosis, 
isolated PAH; renal crisis rare 
RNA polymerase III dcSSc Extensive skin, tendon friction 
rubs, renal crisis 
U3-RNP dcSSc PAH, ILD, scleroderma renal 
crisis, myositis 
Th/T0 lcSSc ILD, PAH 
PM/Scl lcSSc Calcinosis, myositis 
 
Fibrosis 
Fibrosis affecting multiple organs distinguishes SSc from other 
connective tissue diseases. Fibrosis characteristically follows, and is 
thought to be a consequence of, autoimmunity and vascular damage. The 
process, characterized by progressive replacement of normal tissue 
architecture with dense connective tissue, accounts for substantial 
morbidity and mortality. Fibroblasts are mesenchymal cells responsible 
for maintaining the functional and structural integrity of connective 
tissue. When activated by TGF-β and related factors, fibroblasts 
proliferate, migrate, secrete collagens and extracellular matrix, growth 
 factors, and cytokines, and transdifferentiate into myofibroblasts. The 
rapid and self-limited physiologic repair program becomes sustained and 
amplified in pathologic fibrosis, resulting in the irreversible accumulation 
of scar tissue.  
PATHOLOGY 
The distinguishing pathologic hallmark of SSc is the combination 
of widespread capillary loss and obliterative vasculopathy of small 
arteries and arterioles, together with fibrosis in the skin and internal 
organs. The vascular lesion is characterized by intimal proliferation in the 
small and medium-sized arteries, resulting in luminal narrowing. 
Obliterative vasculopathy as a late finding is prominent in the heart, 
lungs, kidneys, and intestinal tract. Fibrosis is found in the skin, lungs, 
gastrointestinal tract, heart, tendon sheath, perifascicular tissue 
surrounding skeletal muscle, and some endocrine organs. In these tissues, 
accumulation of connective tissue composed of endothelin-1m collagens, 
fibronectin, proteoglycans, and other structural macromolecules 
progressively disrupts normal architecture, resulting in functional 
impairment of affected organs. 
Skin:   In the skin, fibrosis causes dermal expansion and obliteration of 
the hair follicles, sweat glands, and other appendages. Collagen fiber 
 accumulation is most prominent in the reticular dermis, and the fibrotic 
process invades the subjacent adipose layer with entrapment of fat cells. 
Lungs: Patchy infiltration of the alveolar walls with T lymphocytes, 
macrophages, and eosinophils occurs in early disease. With progression, 
interstitial fibrosis and vascular damage dominate. Pulmonary fibrosis is 
characterized by expansion of the alveolar interstitium, with 
accumulation of collagen and other connective tissue proteins. The most 
common histologic pattern in SSc is fibrotic nonspecific interstitial 
pneumonia. 
Gastrointestinal Tract: The lower esophagus is frequently involved, 
with prominent atrophy of the muscular layers.  Replacement of the 
normal intestinal tract architecture results in diminished peristaltic 
activity, with gastroesophageal reflux, dysmotility, and small-bowel 
obstruction. Chronic reflux is associated with esophageal inflammation, 
ulcerations, and stricture formation and may lead to Barrett's metaplasia.  
Kidneys: In the kidneys, lesions in the interlobular and arcuate arteries 
predominate. Patients with scleroderma renal crisis show dramatic 
changes in small renal arteries with reduplication of elastic lamina, 
marked intimal proliferation, and narrowing of the lumen, often 
accompanied by thrombosis and microangiopathic hemolysis.  
 Heart: The heart is frequently affected, with prominent involvement of 
the myocardium and pericardium. The characteristic arteriolar lesions are 
concentric intimal hypertrophy and luminal narrowing, accompanied by 
contraction band necrosis reflecting ischemia-reperfusion injury, and 
patchy myocardial fibrosis that may also affect the conduction system. 
CLINICAL FEATURES 
Virtually every organ is affected in SSc. While dcSSc is associated 
with prominent and early internal organ involvement, lcSSc presents with 
long-standing Raynaud's phenomenon, indolent skin lesions, limited 
internal organ involvement, and a better prognosis. The initial 
presentation is quite different in the diffuse and the limited cutaneous 
forms of the disease.  
ORGAN INVOLVEMENT 
Raynaud's Phenomenon: 
Raynaud's phenomenon is an episodic vasoconstriction in the 
fingers and toes that occur in virtually every patient with SSc. 
Vasoconstriction may also affect the tip of the nose and earlobes. Attacks 
are triggered by exposure to cold, a decrease in temperature, emotional 
stress, and vibration. Typical attacks start with pallor, followed by 
cyanosis of variable duration. Eventually erythema develops 
 spontaneously or with rewarming of the digit. The progression of the 
three color phases reflects the underlying pathogenic mechanisms of 
vasoconstriction, ischemia, and reperfusion. It is frequently associated 
with ischemic lesions and infarction in the digits. 
Skin Features: 
Early-stage SSc is associated with edematous skin changes. Skin 
thickening is the hallmark that distinguishes SSc from other connective 
tissue diseases. The distribution of skin thickening is invariably 
symmetric and bilateral. It typically starts in the fingers, and then 
characteristically advances from distal to proximal extremities in an 
ascending fashion. Hyperpigmentation of the skin also occur. Vitiligo-
like hypopigmentation may occur and the pigment loss spares the 
perifollicular areas, the skin may have a "salt-and-pepper" appearance, 
most prominently on the scalp, upper back, and chest. Dermal sclerosis 
and fixed flexion contractures of the fingers may be present. The 
characteristic facial features are „mauskopf‟ facies, microstomia, radial 
furrowing around the mouth, reduced mobility of the eyelids, cheeks & 
mouth and pinched, beak-like nose. The skin is firmly bound to the 
subcutaneous fat (tethering) and undergoes thinning and atrophy. 
Telangiectasiae are prominent on the face, hands, lips, and oral mucosa. 
Breakdown of atrophic skin leads to chronic ulcerations at the extensor 
 surfaces of the proximal interphalangeal joints, the volar pads of the 
fingertips, and bony prominences such as the elbows and malleoli. 
Healing of ischemic fingertip ulcerations leaves characteristic fixed 
digital „pits‟ (stellate scar). Loss of soft tissue at the fingertips due to 
ischemia is frequent and may be associated with striking resorption of the 
terminal phalanges (acro-osteolysis). Calcium deposits occur in the skin 
and soft tissues. Calcinosis cutis is most common in patients with lcSSc 
who are positive for anticentromere antibodies.  
Pulmonary Features: 
Pulmonary involvement can be documented in most patients with 
SSc. There are two main types of significant pulmonary involvement: 
Intestitial Lung Disease (ILD) and Pulmonary Artery Hypertension 
(PAH). Less frequent pulmonary manifestations of SSc include aspiration 
pneumonitis, pulmonary hemorrhage due to endobronchial telangiectasia, 
obliterative bronchiolitis, pleural reactions, restrictive ventilatory defect 
due to chest wall fibrosis, spontaneous pneumothorax, and drug-induced 
lung toxicity. The incidence of lung cancer, particularly 
bronchioloalveolar carcinoma is more in patients with SSc. The most 
frequent presenting respiratory symptoms: exertional dyspnea, fatigue, 
and reduced exercise tolerance are often subtle and slowly progressive. A 
chronic dry cough may be present. Physical examination may reveal 
 "Velcro" crackles at the lung bases. Most SSc deaths are now the result of 
end-stage lung disease (both interstitial and pulmonary vascular).   
Upper Gastrointestinal Tract Involvement: 
Xerostomia, reduced oral aperture, periodontal disease and 
resorption of the mandibular condyles are frequent. The frenulum of the 
tongue may be shortened. Symptoms of gastroesophageal reflux disease 
(GERD) develop early. Severe erosive esophagitis, esophageal strictures 
and Barrett's esophagus can occur. Gastroparesis with early satiety, 
abdominal distention, and aggravated reflux symptoms is common. 
Gastric antral vascular ectasia (GAVE) in the antrum may occur. These 
subepithelial lesions, reflecting the diffuse small-vessel vasculopathy of 
SSc, are described as "watermelon stomach" due to their endoscopic 
appearance. Patients with GAVE can have recurrent episodes of 
gastrointestinal bleeding, resulting in chronic unexplained anemia. 
Lower Gastrointestinal Tract Involvement: 
Impaired intestinal motility may result in malabsorption and 
chronic diarrhea secondary to bacterial overgrowth. Disturbed intestinal 
motor function can also cause intestinal pseudoobstruction. Colonic 
involvement may cause severe constipation, fecal incontinence, 
gastrointestinal bleeding from telangiectasia, and rectal prolapse. In late-
 stage SSc, wide-mouth sacculations or diverticula occur in the colon, 
occasionally causing perforation and bleeding. An occasional radiologic 
finding is pneumatosis cystoides intestinalis.  Primary biliary cirrhosis 
may coexist with SSc.  
Renal Involvement: Scleroderma Renal Crisis: 
Scleroderma renal crisis, the most dreaded complication of SSc, 
occurs in 10–15% of patients, and almost always within 4 years of the 
onset of the disease. The pathogenesis involves obliterative vasculopathy 
and luminal narrowing of the renal arcuate and interlobular arteries. 
Progressive reduction in renal blood flow, aggravated by vasospasm, 
leads to juxtaglomerular hyperplasia, increased renin secretion, and 
activation of angiotensin, with further renal vasoconstriction resulting in 
a vicious cycle that culminates in malignant hypertension. Palpable 
tendon friction rubs; pericardial effusion, new unexplained anemia, and 
thrombocytopenia may be harbingers of impending scleroderma renal 
crisis. High risk factors for the development of scleroderma renal crisis 
are  male gender, diffuse cutaneous SSc with extensive and progressive 
skin involvement, and autoantibodies to RNA polymerases I and III. 
 
 
 Cardiac Involvement: 
Cardiac disease occurs more frequently in patients with dcSSc than 
in those with lcSSc, and generally develops within 3 years of the onset of 
skin thickening. Manifestations include pericardial effusions, atrial and 
ventricular tachycardias, conduction abnormalities, valvular 
regurgitation, hypertrophy, and heart failure. Systemic and pulmonary 
hypertension and lung and renal involvement may also impact on the 
heart. Despite the presence of widespread obliterative vasculopathy, the 
frequency of clinical or pathologic epicardial coronary artery disease in 
SSc is not increased. Clinically evident cardiac involvement in SSc is a 
poor prognostic factor. 
LABORATORY FEATURES 
The diagnosis of SSc is made primarily on clinical grounds and is 
generally straightforward in patients with established disease. Antinuclear 
autoantibodies are present in almost all patients with SSc. Autoantibodies 
against topoisomerase-I (Scl-70) and centromere are specific for SSc and 
are mutually exclusive. Topoisomerase-I antibodies are detected in 31% 
of patients with dcSSc, but in only 13% of patients with lcSSc; 
conversely, anticentromere antibodies are detected in 38% of patients 
with lcSSc, but in only 2% of patients with dcSSc. Anticentromere 
 antibodies are commonly associated with lcSSc and PAH, and only rarely 
with cardiac or renal involvement or significant ILD. Anti 
Topoisomerase-I-positive patients have reduced survival compared to 
those without this antibody; whereas anti centromere antibody-positive 
patients have improved survival compared to those without this antibody.  
TREATMENT 
To date, no therapy has been shown to significantly alter the 
natural history of SSc. In contrast, multiple interventions are highly 
effective in alleviating the symptoms and in slowing the progression of 
the cumulative organ damage. Optimal management incorporates the 
following principles: prompt and accurate diagnosis; classification and 
risk stratification based on clinical and laboratory evaluation; early 
recognition of organ-based complications and assessment of their extent, 
severity, and likelihood of deterioration; regular monitoring for 
progression, disease activity, and response to therapy; and continuing 
patient education.  
 Disease-Modifying Therapy: Immunosuppressive Agents 
Immunosuppressive agents effective in other connective tissue 
diseases have generally shown modest or no benefit in the treatment of 
SSc. Glucocorticoids may be useful for alleviating stiffness and aching in 
 early-stage dcSSc, but do not influence the progression of skin or internal 
organ involvement. Furthermore, their use in high doses is associated 
with an increased risk of scleroderma renal crisis. Cyclophosphamide has 
been evaluated in the treatment of SSc in retrospective and prospective 
controlled clinical trials. The beneficial effect of cyclophosphamide on 
lung function wanes upon discontinuation of therapy. In small clinical 
trials in SSc, methotrexate treatment was associated with a modest 
improvement in skin scores. Mycophenolate mofetil treatment was 
associated with improved skin induration in uncontrolled studies and was 
generally well tolerated. The use of immunomodulatory agents such as 
cyclosporine, azathioprine, rituximab, extracorporeal photophoresis, 
imatinib, thalidomide, or rapamycin for the treatment of SSc is currently 
not well supported by the literature.  
Anti-Fibrotic Therapy 
D-Penicillamine has been extensively used as an antifibrotic agent. 
Retrospective studies in SSc indicated that D-penicillamine stabilized and 
improved skin induration, and prevented new internal organ involvement. 
Vascular Therapy 
The goal of vascular therapy is to control Raynaud's phenomenon, 
prevent the development and enhance the healing of ischemic 
 complications, and slow the progression of obliterative vasculopathy. 
Patients with Raynaud's phenomenon should dress warmly, minimize 
cold exposure or stress, and avoid drugs that could precipitate or 
exacerbate vasospastic episodes. Angiotensin II receptor blockers such as 
losartan are effective and generally well tolerated. Some patients with 
Raynaud's phenomenon may require 1-adrenergic receptor blockers (e.g., 
prazosin), 5-phosphodiesterase inhibitors (e.g., sildenafil), serotonin 
reuptake inhibitors (e.g., fluoxetine), topical nitroglycerine, and 
intravenous prostaglandins. Low-dose aspirin and dipyridamole prevent 
platelet aggregation and may have a role as adjunctive agents. In patients 
with ischemic finger ulcerations, the endothelin-1 receptor antagonist 
bosentan reduces the development of new ulcers.  
Treatment of Gastrointestinal Complications 
Patients with GERD should be instructed to elevate the head of the 
bed and eat frequent small meals. Proton pump inhibitors reduce acid 
reflux. vascular ectasia in the gastric antrum (watermelon stomach) is 
amenable to treatment with laser photocoagulation. Bacterial overgrowth 
due to small-bowel dysmotility should be treated with short courses of 
rotating broad-spectrum antibiotics such as metronidazole, erythromycin, 
and tetracycline.  
 Treatment of Pulmonary Arterial Hypertension (PAH) 
When PAH is symptomatic, treatment should be started with an 
oral endothelin-1 receptor antagonist or a phosphodiesterase inhibitor 
such as sildenafil. Patients may also require diuretics, oral 
anticoagulation, and digoxin when appropriate. Prostacyclin analogues 
such as epoprostenol or treprostinil can be administered intravenously or 
by continuous subcutaneous infusion. 
Treatment of Renal Crisis 
Treatment should be started promptly with short-acting ACE 
inhibitors, with the goal of achieving rapid normalization of the blood 
pressure. A majority of patients may need short term or permanent renal 
replacement therapy. High risk patients with early SSc and extensive and 
progressive skin involvement should be instructed to monitor their blood 
pressure daily and report significant alterations immediately. Potentially 
nephrotoxic drugs should be avoided, and glucocorticoids used only 
when absolutely necessary, and at low doses.  
COURSE   
 The natural history of SSc is highly variable and difficult to 
predict. Patient with dcSSc have a more rapidly progressive disease and 
worse prognosis than those with lcSSc.  
 PROGNOSIS 
SSc confers a substantial increase in the risk of premature death, 
with age- and gender-adjusted mortality rates that are fivefold to 
eightfold higher compare to the general population. In one population-
based study of SSc patients with all forms of the disease, the median 
survival was 11 years. In patients with dcSSc, 5- and 10-year survivals 
are 70% and 55%, respectively, whereas in patients with lcSSc, 5- and 
10-year survivals are 90% and 75%, respectively.  
PULMONARY AND CARDIAC MANIFESTATIONS OF 
SYSTEMIC SCLEROSIS 
Interstitial Lung Disease (ILD): 
Although ~90% of SSc patients have been found to have 
pulmonary interstitial fibrotic changes at postmortem examination or on 
high-resolution computed tomography (HRCT) of the chest, only ~40% 
develop moderate or severe restrictive pulmonary disease on physiologic 
pulmonary function testing (forced vital capacity [FVC] of  ≤75% of 
predicted)[17]. ILD and pulmonary fibrosis cause restrictive pulmonary 
function defect with impaired gas exchange, characterized on PFT by 
decreased FVC and DLCO but unaffected flow rates. Clinically 
significant ILD develops in 16–43% of patients with SSc. Risk factors 
 include male gender, African American race, diffuse skin involvement, 
severe gastroesophageal reflux, and the presence of topoisomerase-I 
autoantibodies, as well as a low FVC or DLCO at initial presentation. In 
patients who develop significant ILD, the most rapid progression in lung 
disease occurs early in the course of the disease (within the first 3 years), 
when the FVC can decline by 30% per year. The histologic pattern on 
lung biopsy may be helpful in predicting the risk of progression of ILD. 
The most common pattern in SSc, nonspecific interstitial pneumnia, 
carries a better prognosis than usual interstitial pneumonia. The earliest 
interstitial changes in SSc interstitial lung disease (ILD) occur in the 
subpleural areas in the posterior bases of both lungs (17).  
ETIOPATHOGENESIS: 
Although it is clear that ILD in SSc is associated with interstitial 
and alveolar inflammation, pulmonary vascular abnormalities and 
interstitial fibrosis, it is not clear which, if any, are the primary events. It 
may well be that there is another as yet unidentified process which, once 
initiated, leads to all these downstream events. There are strong 
suggestions, however, that inflammation (seen on lung biopsy or in the 
bronchoalveolar lavage [BAL] fluid) is an early process and that when 
present, it predicts progressive decline in physiologic lung function 
measured primarily as %FVC). Although long felt to be the result of a 
 bland fibrosing process, the “alveolitis” associated with SSc lung disease 
is now known to be associated with an active, inflammatory process that 
culminates in fibrosis and significant alteration of the pulmonary 
microarchitecture. Numerous studies have confirmed the presence of pro-
inflammatory and profibrotic cytokines in the BAL fluid obtained from 
SSc patients with ILD. For example, levels of the chemokine IL-8 are 
elevated, perhaps contributing to the neutrophilic alveolitis characteristic 
of SSc ILD. Tumor necrosis factor-alpha (TNF-alpha) levels are also 
elevated (in serum and BAL fluid) and have been shown to correlate 
inversely with FVC. Potent fibroblast mitogens (eg, platelet-derived 
growth factor [PDGF] and thrombin) and profibrotic factors (eg, 
transforming growth factor-beta [TGF-beta] and connective tissue growth 
factor [CTGF]) are elevated in SSc BAL fluid and may play a role in the 
pathogenesis of ILD in SSc. 
SYMPTOMS: 
Dyspnea is the most common complaint of patients with ILD and 
when severe is a most debilitating symptom. With mild degrees of ILD, 
the dyspnea usually becomes apparent only with exertion. By the time 
dyspnea is occurring at rest, it is usually a sign that the lung disease is 
moderate or severe (either from ILD or from pulmonary vascular 
disease). Cough is another common symptom of lung fibrosis. Usually, 
 the cough is nonproductive and made worse by exertion. A productive 
cough, or hemoptysis, requires further evaluation to rule out such 
conditions as aspiration pneumonia or neoplasm. 
INVESTIGATIONS: 
Pulmonary Function Testing 
           Pulmonary function testing is a valuable tool for evaluating the 
respiratory system. Insight into underlying pathophysiology can often be 
gained by comparing the measured values for pulmonary function tests 
obtained on a patient at any particular point with normative values 
derived from population studies. The percentage of predicted normal is 
used to grade the severity of the abnormality. PFTs can include simple 
screening spirometry, formal lung volume measurement, diffusing 
capacity for carbon monoxide, and arterial blood gases.  Pulmonary 
function studies measure and record the properties of four lung 
components. These include the airways (large and small), lung 
parenchyma (alveoli, interstitium), pulmonary vasculature, and the 
bellows-pump mechanisms. 
Spirometry: 
           Spirometry is the most commonly used lung function screening 
study.   A spirogram is a graphic representation of bulk air movement 
 depicted as a volume-time tracing or as a flow-volume tracing. Values 
generated from a simple spirogram provide important graphic and 
numeric data regarding the mechanical properties of the lungs, including 
airflow (forced expiratory volume in 1 second [FEV1]) and exhaled lung 
volume (FVC). The most common parameters measured in Spirometry 
are Vital capacity (VC), Forced vital capacity (FVC), Forced expiratory 
volume (FEV) at timed intervals of 0.5, 1.0 (FEV1), 2.0, and 3.0 seconds, 
Forced expiratory flow 25–75% (FEF 25–75) and Maximal voluntary 
ventilation (MVV). Results are usually given in both raw data (litres, 
litres per second) and percent predicted - the test result as a percent of the 
"predicted values" for the patients of similar characteristics (height, age, 
sex, race and weight). The interpretation of the results can vary 
depending on the physician and the source of the predicted values. 
Generally speaking, results nearest to 100% predicted are the most 
normal and results over 80% are often considered normal[18].  
Forced Expiratory Volume in one Second (FEV1): 
            The FEV1 is the most widely used parameter to measure the 
mechanical properties of the lungs. In normal persons, the FEV1 accounts 
for the greatest part of the exhaled volume from a spirometric maneuver 
and reflect mechanical properties of the large and the medium-sized 
airways. In a normal flow-volume loop, the FEV1 occurs at about 75% to 
 85% of the FVC. This parameter is reduced in obstructive and restrictive 
disorders.  
Forced Vital Capacity 
              FVC is a measure of lung volume and is usually reduced in 
diseases that cause the lungs to be smaller. Such processes are generally 
termed restrictive and can include disorders of the lung parenchyma, such 
as pulmonary fibrosis, or of the bellows, including kyphoscoliosis, 
neuromuscular disease, and pleural effusion. However, a reduction in 
FVC is not always due to reduced total volumes and can occur in the 
setting of large lungs hyperinflated due to severe airflow obstruction and 
air trapping, as in emphysema. This phenomenon referred to as pseudo 
restriction. Reduced FVC can occur despite a normal or increased total 
lung volume (19). 
FEV1/FVC ratio (FEV1%) 
           In healthy adults this should be approximately 75–80%. In 
obstructive diseases (asthma, COPD, chronic bronchitis, emphysema) 
FEV1 is diminished because of increased airway resistance to expiratory 
flow and the FVC may be decreased (for instance by premature closure of 
airway in expiration). This generates a reduced value (<80%, often 
~45%). In restrictive diseases (such as pulmonary fibrosis) the FEV1 and 
 FVC are both reduced proportionally and the value may be normal or 
even increased as a result of decreased lung compliance. 
MEASUREMENT OBSTRUCTIVE 
PATTERN 
RESTRICTIVE 
PATTERN 
FVC Reduced or normal reduced 
FEV1 reduced normal or reduced 
FEV1/FVC reduced normal or increased 
TLC normal or increased reduced 
 
Diffusing Capacity 
             Spirometry and lung volumes elucidate the mechanics of 
ventilation but do not address the gas-transfer function of the lung. With 
use of a highly diffusable gas (carbon monoxide [CO]) as a surrogate for 
oxygen, the diffusing capacity of lung for CO (DLCO) estimates the 
patient‟s ability to absorb alveolar gases. Diffusion in the lungs is most 
efficient when the surface area for gas transfer is high and the blood is 
readily able to accept the gas being transferred. It is thus decreased in: 
• Conditions that minimize the ability of the blood to accept and bind the 
gas that is diffusing (eg, anemia) 
• Conditions that decrease the surface area of the alveolar-capillary 
membrane (eg, emphysema, pulmonary embolism) 
 • To a smaller degree, conditions that alter the membrane‟s permeability 
or increase its thickness (eg, pulmonary fibrosis). 
Conversely, conditions resulting in an increased effective pulmonary 
blood volume cause an elevated DLCO. 
            The most frequently abnormal PFT in SSc is the DLCO. 
Unfortunately this test can reflect damage from a multitude of processes, 
including obstructive, restrictive, and pulmonary vascular involvement. 
Fortunately in SSc, obstructive disease is not all that common, and as a 
result, a reduced DLCO usually reflects restrictive and/or pulmonary 
vascular disease. FVC on the other hand is a better measure of ILD or 
restrictive lung disease, assuming confounding issues with poor patient 
effort or weak respiratory muscles can be ruled out. 
Chest Radiography: The chest radiograph may be normal in patients 
with early fibrosis. In late stages, chest radiograph shows changes 
identical to that of Interstitial Pulmonary Fibrosis (IPF).  Chest 
radiographs typically show a fine reticular or reticulonodular pattern 
involving the lower lung zones in early stages. With progression of 
disease, the reticular pattern becomes more coarse and diffuse, and 
honeycombing may be seen .It is useful in detecting clinically significant 
pleural effusion 
 High resolution computed tomography: 
         The use of cross sectional images in CT makes it possible to 
distinguish between densities and provide accurate size assessment of 
lesions. With high resolution CT, the thickness of individual cross 
sectional images is approximately 1 to 2 mm rather than the usual 10 mm 
and the images are reconstructed with high spatial resolution algorithms.  
 Chest HRCT is a tool that is much more sensitive in showing 
interstitial changes than is standard chest radiography. The hope is that it 
will also be a tool sensitive enough to find early inflammatory changes 
that will predict outcome (much as BAL). Groundglass (GG) 
opacification (a hazy-appearing opacification through which normal lung 
architecture can be seen) may be such a sign of inflammation, particularly 
if there is little or no obvious fibrotic change in the same area. It is likely 
that HRCT scans may replace BAL as a method to evaluate ILD in SSc 
patients. The advantages of HRCT scans include the noninvasive nature 
of the study, which facilitates serial studies over time, as well as the fact 
that with HRCT both lungs can be examined in their entirety. 
Broncho Alveolar Lavage: 
         The Bronchoscope can be used to sample material from the distal 
pulmonary parenchyma. The upper airway is anaesthetized and the 
 bronchoscope is introduced and wedged into a subsegmental airway. 
Aliquots of sterile saline are introduced through the scope. This allows 
sampling of the cells and organisms from the alveolar spaces. The lavage 
is filtered and the cells are stained with Papanicolaou‟s method and 
differential count is performed. 
The definitions of alveolitis that best predict declines in FVC and 
DLCO in SSc relate primarily to increases in polymorphonuclear (PMN) 
and eosinophilic (EOS) leukocytes in BAL fluid. One common definition 
of alveolitis includes the presence of ≥3% PMN and/or ≥2% EOS 
leukocytes in the BAL fluid. Although lymphocytosis (≥20% of BAL 
cells) may accompany increased %PMN and %EOS leukocytes, it is less 
clear what the presence of an isolated lymphocytosis means with regard 
to future lung function or therapy in SSc. Using definitions similar to the 
one listed above, several studies have shown that the presence of 
increased PMN and/or EOS leukocytes in BAL fluid predicts continued 
loss of FVC and DLCO. 
Open Lung Biopsy: 
The “gold standard” for the evaluation of restrictive lung disease is 
the open lung biopsy that can show the type and degree of inflammation 
as well as the degree of fibrosis. It can also show the presence of other 
 processes that may mimic or confound SSc ILD (ie, sarcoidosis, 
bronchiolitis obliterans with organizing pneumonia [BOOP], aspiration 
from gastroesophageal reflux). The predominant lesion in SSc is 
nonspecific interstitial pneumonitis (NSIP). Because the test is invasive, 
is associated with significant morbidity even if done thorascopically, can 
give differing results depending on what area(s) are selected for biopsy, 
and may not provide accurate prognostic or therapeutic guidance, it is not 
considered the test of choice. 
DIFFERENTIAL DIAGNOSIS  
Pulmonary vascular involvement with pulmonary hypertension and 
cardiomyopathy with diastolic dysfunction can occur in isolation or 
concurrently with ILD and produces symptoms similar to ILD. Occult 
GERD may present with atypical symptoms, such as cough, asthma-like 
respiratory complaints, wheezing, pneumonia, or hoarseness (symptoms 
not usually associated with GERD). Because occult GERD is so 
common, it must always be considered to be part of the problem in 
patients with respiratory complaints and should be treated aggressively 
with antireflux measures. Pulmonary infection (often the result of occult 
or overt reflux with mini-aspirations) may also confound the evaluation 
and management of ILD and should be considered in all SSc patients who 
report increased dyspnea and cough, especially if the cough is productive.   
 PULMONARY ARTERIAL HYPERTENSION 
Pulmonary arterial hypertension (PAH) is the leading cause of 
death in patients with systemic sclerosis (SSc) with limited scleroderma 
and increasingly recognized as a cause of pulmonary morbidity in diffuse 
scleroderma as well. PAH can occur in the absence of interstitial lung 
disease, most typically in patients with SSc with limited scleroderma, or 
as a reflection of both vascular and microvascular injury in the setting of 
diffuse scleroderma. PAH is a progressive disease characterized by 
increased pulmonary artery pressure (PAP) and pulmonary vascular 
resistance (PVR), ultimately producing right heart failure and death. Of 
all CTDs, PAH is most often seen in SSc. 
 Definition  
PAH is defined as a mean pulmonary artery pressure (PAP) of >25 
mm Hg at rest, or >30 mm Hg during exercise, the absence of an elevated 
pulmonary capillary wedge pressure or left ventricular end diastolic 
pressure (ie, <15 mm Hg) and a pulmonary vascular resistance >3 U • M².  
 PATHOPHYSIOLOGY AND NATURAL HISTORY 
Regardless of etiology, PAH is characterized by pulmonary 
vascular smooth muscle hypertrophy, intimal fibrosis, and in situ 
thrombosis. Recent evidence suggests endothelial dysfunction is 
 important in its pathobiology. PAH is a very significant pulmonary 
complication in SSc. One series reported that 33% to 63% of pulmonary-
related deaths in patients with SSc were due to PAH. Others have 
observed that patients with isolated PAH had a 2-year survival rate of 
40% compared with 88% of SSc patients without PAH. 
DIAGNOSIS 
Slowly progressive exertional dyspnea is the most common 
symptom of PAH. The diagnosis of PAH is a process of exclusion. In the 
absence of other causes, dyspnea should prompt evaluation for PAH in 
SSc patients, particularly those with lcSSc. Diagnostic testing of patients 
suspected of having PAH should begin with noninvasive tests to identify 
potential underlying diseases and rule out alternative diagnoses. These 
tests include electrocardiography, echocardiography, pulmonary function 
tests, chest radiography, ventilation-perfusion lung scan, and high 
resolution CT. In patients in whom noninvasive tests suggest PAH, right 
heart catheterization is necessary to confirm the diagnosis. 
2-D Echocardiography with Doppler Interrogation 
Echocardiography can reveal typical features observed in patients 
with PAH: enlarged right heart chambers, right ventricular hypertrophy, 
abnormal interventricular septal position, and a normal to small left 
 ventricle. With Doppler interrogation, the right ventricular systolic 
pressure, which is equal to the pulmonary arterial systolic pressure in the 
absence of pulmonary stenosis, can be estimated by the velocity of the 
tricuspid regurgitation jet. 
Ventilation-Perfusion Lung Scan 
For patients suspected of having isolated PAH, chronic 
thromboembolic disease must be ruled out. If a ventilation-perfusion 
(V/Q) lung scan is read as high probability or indeterminate probability, 
pulmonary angiography is needed to rule out chronic thromboembolic 
disease. In patients with suspected chronic thromboembolic disease, 
multiple larger perfusion defects occur.  
Right Heart Catheterization  
Right heart catheterization is necessary to confirm the diagnosis of 
PAH. The importance of right heart catheterization, when 
echocardiography suggests PAH, is that pulmonary artery pressure 
measurements obtained by right heart catheterization are not estimations 
as they are with echocardiography. Furthermore, left sided heart disease, 
a frequent cause of elevated pulmonary artery pressure ie, PCWP or 
LVEDP > 15 mm Hg, can be ruled out only by right heart catheterization.  
 
  
 
AIMS AND OBJECTIVES 
 
1) To study the pulmonary and cardiac manifestations of 
systemic sclerosis. 
 
 
 
 MATERIALS AND METHODS 
 
Place of study        :  Department of Medicine. Govt. Rajaji Hospital,
    Madurai 
Design                    :  Cross Sectional Study. 
Period of study       :  One year. 
Ethical approval    : Obtained from Institutional Ethical Committee,  
      headed by Dean, Govt. Rajaji Hospital. 
Consent                 :  Informed consent obtained from all patients. 
Financial Support  : Nil 
Conflict of Interest: Nil 
Statistical software:  EPI Info 2008. 
Study population   :  Patients attending Rheumatology OP,   
Dermatology OP, General Medicine OP  
   & Thoracic Medicine OP  with Systemic  
Sclerosis 
 
Inclusion criteria: 
1)   Patients who satisfied American College of  Rheumatology criteria 1980 
for the diagnosis of Systemic Sclerosis, irrespective of age, sex and 
duration of disease. 
 Exclusion criteria: 
1) Previous history of Bronchial asthma/ Chronic Obstructive Airway 
Disease. 
2) Patients with respiratory infections, including pulmonary tuberculosis. 
3) Previous history of pulmonary tuberculosis. 
4) Patients who are smokers. 
5) Patients with occupation prone to develop occupational lung disease. 
6) Those who have disorder like SLE, Rheumatoid Arthritis, MCTD and 
overlap syndromes. 
7) Patients with coronary artery disease, rheumatic heart disease or 
congenital heart disease.  
Thirty two patients attending Rheumatology OP, Dermatology OP, 
Thoracic Medicine OP or General Medicine OP and the corresponding 
wards, Govt. Rajaji Hospital, Madurai, who were diagnosed to have 
Systemic Sclerosis, were selected for the study. 
        The selected patients were evaluated with detailed history regarding 
the duration of disease, symptoms, relevant past history, habits and 
occupation. 
          A detailed dermatological examination which includes type and 
extension of skin thickening was done and the Modified Rodnan Skin 
Score was calculated. Other dermatological manifestations like 
sclerodactily, pitted scar on the pulp of fingers, hyper pigmentation, 
telangectasia, salt & pepper lesions, skin ulcers, calcinosis cutis, 
microstomia and flexion contractures of the fingers also noted. A detailed 
respiratory system examination with particular emphasis to the presence 
of pleural effusion, Velcro crackles and wheeze conducted. 
Cardiovascular system of the patient is also examined in detail.  
        Hemoglobin, White blood cell count, Differential count, ESR, Blood 
Urea, Serum Creatinine, Blood sugar, ECG, Chest X ray were done for 
all patients. The antibody profile of the patients which include ANA, anti 
ds DNA, Scl 70 antibody and anti centromere antibody was also done. 
After assessing baseline clinical and laboratory parameters, all 
patients were subjected to spirometric evaluation, High Resolution 
Computerized Tomography (HRCT), and ECHO Cardiogram.   
          The Spirometry was performed using Knudsen‟s computerized 
Spirometer.  All the Spirometric parameters were expressed as percentage 
of predicted value for that particular age, sex, height, and weight 
comparable to South Indian population defined by Knudsen et al. 
          The entire test was repeated on three occasions and the best of the 
three readings were taken. Among the various spirometric parameters, the 
following were analyzed. 
1. Forced Vital Capacity (FVC). 
2. Forced Expiratory Volume in first second (FEV1). 
3. Percentage of FVC expelled as FEV1 (FEV1/FVC) 
        All the patients were subjected to HRCT after getting informed 
consent. Serial slices 2 mm in width and 10 mm apart were taken from 
the apex of the lung to base and reconstructed on a High-resolution bone 
algorithm. HRCT was done from the Department of Radiology, Govt. 
Rajaji Hospital, Madurai. Reports were given by qualified Radiologists.  
 ECHO cardiogram was done at the Department of Cardiology, 
Govt. Rajaji Hospital, Madurai with ALOKA ProSound 4000 machine.      
   The information collected regarding all the selected cases were 
recorded in a master chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2008). Using 
the software range, frequencies, percentage, mean, standard deviation and 
p value were calculated.  P value of < 0.05 was taken as significant. 
 
 RESULTS AND ANALYSIS OF OBSERVED DATA 
TABLE 1. SEX DISTRIBUTION AMONG PATIENTS: 
Sex No. of Patients % 
Male 6 18.75% 
Female 26 81.25% 
Total 32 100% 
 
          In this study out of 32 patients, 26 are females and the rest 6 are 
males. ie 81.25% are females and 18.75% are males. The male to female 
ratio is 1:4.33 
TABLE 2 : AGE DISTRIBUTION OF PATIENTS 
Age group Female Male Total No. % 
20 – 29 yrs 2 4 6 18.75% 
30 - 39 yrs 9 0 9 28.12% 
40 - 49 yrs 9 1 10 31.25% 
50 – 59 yrs 6 1 7 21.88% 
TOTAL 26 6 32 100% 
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 The age of the patient ranges between 20 years and 58 years. The 
average age of the patients is 39.28 years. Most patients come under the 
age group 40-49 years.  
TABLE 3: DURATION OF SYMPTOMS: 
Duration of symptoms No. of patients % 
1 – 3 years 21 65.62% 
4 – 6 years 7 21.88% 
≥7 years 4 12.5% 
TOTAL 32 100% 
    
   65.62% patients had the symptoms for a period of 1-3 years. The mean 
duration is 3.16 years.                                                                                                     
TABLE 4:   DISEASE SUBTYPES 
 MALE % FEMALE % TOTAL % 
dcSSc 6 100 11 42.31% 17 53.12% 
lcSSc 0 0 15 57.69% 15 46.88% 
TOTAL 6 100 26 100% 32 100% 
  
   
DISEASE SUBTYPES: NO. OF PATIENTS 
 
 53.12% of the study population had diffuse cutaneous systemic 
sclerosis and the rest 46.88% had limited cutaneous systemic sclerosis. 
All the male patients had diffuse cutaneous systemic sclerosis and 
nobody comes under limited cutaneous subset. Among female patients 
57.69% had limited cutaneous systemic sclerosis and the rest 42.31% had 
diffuse cutaneous systemic sclerosis. 
TABLE 5:  PRSENCE OF RAYNAUD’S PHENOMENON 
 
RAYNAUD‟S 
PRESENT 
RAYNAUD‟S 
ABSENT 
TOTAL 
 NO. % NO. % NO. % 
dcSSc 9 52.94% 8 47.06% 17 100% 
lcSSc 11 73.33% 4 26.67% 15 100% 
 
52.94% of the patients with diffuse cutaneous systemic sclerosis 
had Raynaud‟s phenomenon. Among patients with limited cutaneous 
systemic sclerosis 73.33% had Raynaud‟s phenomenon. 62.5% of the 
whole study population had Raynaud‟s phenomenon. 
 
 
   DISEASE SUBTYPES: % OF PATIENTS 
 
 
  PRSENCE OF RAYNAUD’S PHENOMENON 
 
 
 TABLE 6: PATTERN OF SYMPTOMS AMONG PATIENTS: 
SYMPTOM 
dcSSc - TOTAL 17 lcSSc - TOTAL 15 
NO. OF PTS % NO.OF PTS % 
RAYNAUD‟S 
PHENOMENON 
9 52.95% 11 73.33% 
ARTHRITIS 10 58.82% 12 80% 
SICCA 4 23.53% 6 40% 
DIFF.IN MOUTH 
OPENING 
15 88.24% 14 93.33% 
GERD 13 76.47% 14 93.33% 
DYSPHAGIA 8 47.06% 12 80% 
 
Both in dcSSc and lcSSc subsets of systemic sclerosis 
gastrointestinal symptoms predominate. 88.24% of patients with dcSSc 
had difficulty in opening of mouth and 76.47% of them had gastro 
oesophageal reflux symptoms. Among lcSSc subset patients the 
prevalence of these symptoms was 93.33%. 
 
 
 TABLE 7: 
CARDIOPULMONARY SYMPTOMS AMONG PATIENTS 
 dcSSc - TOTAL 17 lcSSc - TOTAL 15 
NO. OF PTS % NO.OF PTS % 
DYSPNOEA 14 82.35% 13 86.67% 
DRY COUGH 7 41.18% 9 60% 
HAEMOPTYSIS 1 5.9% 0 0% 
CHEST PAIN  3 17.65% 6 40% 
PALPITATION 4 23.53 6 40% 
SYNCOPE 0 0 2 13.33% 
 
Among cardiopulmonary symptoms, in both subset of  the disease 
dyspnoea on excertion is the predominating symptom. 82.35% of patients 
with dcSSc had dyspnoea and 86.67% of patients with lcSSc had 
dyspnoea on excertion. 41.18% of dcSSc patients and 60% of lcSSc 
patients had dry cough. 
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 TABLE 8  
CLINICAL PARAMETERS 
 dcSSc – TOTAL 17 lcSSc – TOTAL 15 
CLINICAL FEATURES NO.OF PTS % NO.OF PTS % 
CYANOSIS 0 0% 0 0% 
CLUBBING 1 5.88% 5 33.33% 
PEDAL EDEMA 4 23.53% 3 20% 
HYPER PIGMENT 17 100% 13 86.67% 
TELENGECTASIA 0 0% 0 0% 
SALT&PEPPER 16 94.12% 11 73.33% 
SKIN ULCER 4 23.53% 2 13.33% 
CALCINOSIS CUTIS 0 0% 2 13.33% 
STELLATE SCAR 17 100% 15 100% 
MICROSTOMIA 16 94.12% 14 93.33% 
FLEX.CONTRACTURE 10 58.82% 12 80% 
SCLERODACTYLY 17 100% 15 100% 
VELCRO CRACKLES 9 52.94% 7 46.67% 
PLEURAL EFFUSION 0 0% 1 6.67% 
↑ JVP 2 11.76% 1 6.67% 
LPH 1 5.88% 1 6.67% 
LOUD P2 4 23.53% 3 20% 
 
Most of the patients had typical dermatological manifestations. All 
of them had pitted scar at the pulp of fingers in both the disease subtypes.  
All of them had sclerodactily also. 52.94% of patients with dcSSc  and 
46.67% of patients with lcSSc had Velcro crackles at their lung bases. 
 
 TABLE 9:  DISEASE PARAMETERS 
 dcSSc – TOTAL 17 lcSSc – TOTAL 15 
PARAMETER RANGE MEAN SD RANGE MEAN SD 
DURATION 1-7 2.82 1.94 1-8 3.53 2.36 
Hb g% 8.2-13.6 10.3 1.62 8.2-14.2 10.11 1.49 
ESR mm/1
st
 hr 52-133 40.58 20.38 5-100 35.07 24.57 
MRSS 12-32 21.06 5.93 11-18 14.27 2.37 
 
The average duration of the disease (dcSSc) is 2.82years and that 
of  lcSSc is 3.53 years. The mean haemoglobin concentration is 10.3g% 
and 10.11g% respectively. dcSSc subset of patients had an average ESR 
of 40.58mm/1
st
hr and lcSSc patients had 35.07mm/1
st
 hr. The Modified 
Rodnan Skin Score of patients with dcSSc ranges from 12 to 32 and the 
average score is 21.06. For patients with lcSSc the score ranges from 11 
to 18 and the average score is 14.27. 
 
 
 
 
 TABLE 10:  POSITIVE ANTIBODY PATTERN 
ANTIBODY 
dcSSc–TOTAL 17 lcSSc–TOTAL 15 TOTAL-32 
Number % Number % Number % 
ANA 14 82.35% 13 86.67% 27 84.38% 
Scl 70 antibody 6 35.29% 2 13.33% 8 25% 
Anticentromere 0 0% 6 40% 6 18.75% 
 
Anti nuclear antibody is positive in 82.35% of patients with dcSSc 
subset of the disease and in LlSSc subset the ANA positivity is 86.67%. 
The Scl 70 antibody is positive in 35.29% of patients with dcSSc and 
13.33% of patients with lcSSc exhibits positivity to this antibody. Anti 
Centromere antibody is positive in 40% patients with lcSSc and none of 
the patients with dcSSc have anti centromere antibody. 
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 TABLE 11: ABNORMAL IMAGING REPORTS 
 dcSSc –TOTAL 17 lcSSc–TOTAL15 TOTAL-32 
Investigation Number % Number % Number % 
X-RAY CHEST 9 52.94% 11 73.33% 20 62.5% 
HRCT CHEST 12 70.59% 12 80% 24 75% 
PFT 11 64.71% 13 86.67% 24 75% 
 
 Among patients with dcSSc 52.94% has abnormal chest x-ray, 
70.59% shows abnormal HRCT findings and 64.71% has abnormal PFT 
reports. In patients with lcSSc the abnormal reports are higher; 73.33% 
shows abnormal chest x-ray, 80%has abnormal HRCT findings and 
86.6% has abnormal PFT reports. 
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 TABLE 12:  CHEST X-RAY FINDINGS 
 dcSSc –TOTAL 17 lcSSc –TOTAL 15 TOTAL-32 
FINDING NO. % NO. % NO. % 
NORMAL 8 47.06% 4 26.67% 12 37.5% 
RETICULAR 8 47.06% 11 73.33% 19 59.38% 
VOL.LOSS 7 41.18% 5 33.33% 12 37.5% 
PLEURAL 
EFFUSION 
0 0% 1 6.67% 1 3.1% 
 
Most common chest x-ray finding in dcSSc and lcSSc subset 
patients is reticular shadows (47.06% and 73.33% respectively). 1 patient 
with lcSSc had pleural effusion. 
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 TABLE 13:  HRCT FINDINGS 
  
FINDINGS 
dcSSc – 
TOTAL 17 
lcSSc – TOTAL 
15 
Total – 32 
No. % No. % No. % 
NORMAL 6 35.29% 3 20% 9 28.13% 
GROUND GLASS 
OPACITY 
10 58.82% 12 80% 22 68.75% 
RETICULO 
NODULAR 
5 29.41% 8 53.33% 13 40.63% 
HONEY COMBING 10 58.82% 8 53.33% 18 56.25% 
INTERLOBAR 
SEPTAL 
THICKENING 
9 52.94% 10 66.67% 19 59.38% 
PLEURAL 
THICKENING 
8 47.06% 7 46.67% 15 46.88% 
BRONCHIECTASIS 9 52.94% 7 46.67% 16 50% 
NODULES 6 35.29% 6 40% 12 37.5% 
MEDIASTINAL LN 2 11.76% 1 6.67% 3 9.38% 
PLEURAL 
EFFUSION 
1 5.88% 1 6.67% 2 6.25% 
 
The common HRCT findings in patients with dcSSc are ground 
glass opacity (58.82%), honey combing (58.82%), inter lobar septal 
thickening (52.94%) and bronchiectasis (52.94%). In patients with lcSSc 
80% patients shows ground glass opacity, 66.67% shows interlobar septal 
thickening and 53.33% shows reticulonodular and honey combing 
pattern. In both subset of disease 1 patient each has radiologically evident 
pleural effusion. 
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TABLE 14: PATTERN OF PFT FINDINGS 
 dcSSc –TOTAL 17 lcSSc –TOTAL 15 TOTAL -32 
 NO. % NO. % NO. % 
NORMAL 6 35.29% 2 13.33% 8 25% 
RESTRICTIVE 9 52.94% 13 86.67% 22 68.25% 
OBSTRUCTIVE 2 11.76% 0 0% 2 6.25% 
 
52.29% of patients with dcSSc show restrictive pattern in PFT and 
11.76% shows obstructive pattern. Among patients with lcSSc 86.67% 
shows restrictive pattern in PFT. No patients with lcSSc has obstructive 
pattern in PFT. 
 
 
 
 
 
 
  
   
PATTERN OF PFT FINDINGS 
 
 
 
 
 
 
 
 TABLE 15:   PFT PARAMETERS 
 dcSSc lcSSc 
PARAMETER RANGE MEAN SD RANGE MEAN SD 
FVC (Ltr) 1.02-4.41 1.81 0.83 0.87-2.74 1.60 0.48 
FEV1 (Ltr) 0.38-4.17 1.46 0.83 0.85-2.34 1.48 0.41 
FVC% 40-103 68.29 20.25 35-92 64 14.72 
FEV1% 12-114 66.06 27.42 37-89 71 15.15 
FEV1/FCV 14.7-100 81.37 20.41 85-100 92.99 3.76 
 
The mean FVC% of dcSSc patients is 68.29% and the FEV1% is 
66.06%. The average FEV1/FVC of patients with dcSSc is 81.37. 
In patients with lcSSc, the mean FVC% is 64% and the mean 
FEV1% is 71%. They show an average FEV1/FVC of 92.99. 
 
 
 
 
 
 TABLE 16: SEVERTY OF RESTRICTIVE PATTERN: 
SEVERTY dcSSc lcSSc Total 
NO. % NO. % No. % 
MILD 1 11.11% 5 38.46% 6 27.27% 
MODERATE 5 55.56% 5 38.46% 10 45.45% 
SEVERE 3 33.33% 3 23.08% 6 27.27% 
TOTAL 9 100% 13 100% 22 100% 
 
In patients with dcSSc and restrictive pattern in PFT 11.11% have 
mild restriction, 55.56% have moderate restriction and 33.33% have 
severe restriction in PFT. 
Among patients with lcSSc and restrictive pattern in PFT 38.46% 
have mild restriction, 38.46% patients have moderate restriction and the 
remaining 23.08% have severe restriction. 
 Severity of restrictive pattern in pulmonary function test is 
classified according to percentage of predicted FVC(33,34). 
Mild- 70-79%.    Moderate- 50- 69%    Severe - <50% 
 
 SEVERTY OF RESTRICTIVE PATTERN 
 
 
 
 
 
 
 
 
 
 TABLE 17:  PULMONARY MANIFESTATIONS 
DISEASE 
dcSSc – 
TOTAL 17 
lcSSc – 
TOTAL 15 
TOTAL 
32 
NO. % NO. % NO. % 
ILD 11 64.71% 13 86.67% 24 75% 
OBSTRUCTIVE 1 5.88% 0 0% 1 3.13% 
RESTRICT+OBS 1 5.88% 0 0% 1 3.13% 
PLEURAL 
EFFUSIONEFFUSION 
1 5.88% 1 6.67% 2 6.25% 
PULMONARY 
HAEMORRHAGE 
1 5.88% 0 0% 1 3.13% 
 
The commonest pulmonary manifestation found in both subset of 
systemic sclerosis is interstitial lung disease. It is found in 64.71% of 
patients with dcSSc and in 86.67% patients with lcSSc. 1 patient with 
dcSSc had obstructive lung disease and another patient with dcSSc had 
pulmonary haemorrhage. 1 patient from both subset of disease had 
pleural effusion. 
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 TABLE 18  : ILD IN dcSSc 
 
 
SL NO. PARAMETER 
ILD 
PRESENT 
ILD 
ABSENT 
TOTAL 
„P‟ 
VALUE 
Sex 
Male 2 4 6 
 
0.0452 
Female 9 2 11 
Duration of 
symptoms 
≤4 years 7 6 13 
 
0.0908 
>4 years 4 0 4 
MRSS 
≤17 1 4 5  
0.0126 
>17 10 2 12 
Scl 70 
Positive 5 1 6 
0.2146 
Negative 6 5 11 
Anti 
Centromere 
Antibody 
Positive 2 0 2 
0.2635 
Negative 9 6 15 
PFT 
Normal 1 5 6 
0.0021 
Abnormal 10 1 11 
 33.33% of male patients with dcSSc had ILD while 81.82% of 
female patients with dcSSc had ILD. There is a statistically significant 
relationship between sex and ILD in patients with dcSSc ( „P‟ value is 
0.0452). 
  Among those patients with dcSSc and duration of symptoms ≤4 
years 53.85% had ILD.  All patients with duration of symptoms >4 years 
and dcSSc had ILD. The „P‟ value for this relation is 0.0908 which 
implies there is no significant relation exists between these two 
parameters. 
Only 20% of patients with dcSSc and Modified Rodnan Skin Score 
≤17 had ILD. But 83.33% of patients with MRSS >17 had ILD. The „P‟ 
value for this relationship is 0.0126 and there is significant relation exists 
between these two parameters. 
83.33% of the patients with positive Scl 70 antibody had ICD in 
the dcSSc subset. But 54.54% of dcSSc patients with negative Scl 70 
antibody had ILD. The „P‟ value for this association is 0.2146; ie there no 
statistically significant relationship exists between these two parameters. 
Similarly there is no significant relationship exists between 
anticentromere antibody and ILD in patients with dcSSc. 
 There is a significant association between abnormal PFT and ILD. 
10 out of 11(90.9%) patients with abnormal PFT had ILD. Only 1 patient 
out of 6 with normal PFT has ILD (16.67%).   
 TABLE 19: ILD IN lcSSc 
           
In the study population, all the patients with lcSSc are females. 
Among them 13 out of 15 (86.67%) had ILD. There are no male patients 
with lcSSc in the study population.  
80% of lcSSc patients with disease duration ≤4 years had ILD and 
all the lcSSc patients with disease duration >4 years had ILD. There is no 
SL NO. PARAMETER 
ILD 
PRESENT 
ILD 
ABSENT 
TOTAL 
„P‟ 
VALUE 
Sex 
Male 0 0 0 
 
Cannot be 
calculated Female 13 2 15 
Duration of 
Disease 
≤4 years 8 2 10  
0.2825 >4 years 5 0 5 
MRSS 
≤12 4 1 5  
0.5934 >12 9 1 10 
Scl 70 
Positive 2 0 2 
Cannot be 
calculated 
Negative 11 2 13 
Anti 
Centromere 
Antibody 
Positive 5 1 6 
0.756 
Negative 8 1 9 
PFT 
Normal 0 2 2 
0.0001 
Abnormal 13 0 13 
 statistically significant association between duration of lcSSc and 
development of ILD. 
80% of lcSSc patients with MRSS ≤12 and 90% of lcSSc patients 
with MRSS >12 had ILD. There is no statistically significant association 
between MRSS and development of ILD. 
13.33% of lcSSc patients had Scl 70 antibody positivity and all of 
them had ILD. But 84.62% of Scl 70 negative lcSSc patients also had 
ILD. There is no statistically significant association between the Scl 70 
antibody and development of ILD in lcSSc patients. 
40% of lcSSc patients had positive anti centromere antibody and 
among them 83.33% had ILD. 88.89% of anti centromere antibody 
negative lcSSc patients also had ILD. Here also no statistically significant 
association exists between anti centromere antibody and development of 
ILD in lcSSc patients. 
All the 13 lcSSc patients with abnormal PFT had ILD and both the 
2 lcSSc patients with normal PFT do not have ILD. The „P‟ value for this 
association is 0.0001. 
 
 
 
 TABLE 20: ILD IN SYSTEMIC SCLEROSIS SUBTYPES 
 ILD PRESENT ILD ABSENT TOTAL 
„P‟ 
VALUE 
 Number % Number % Number % 
0.1524 dcSSc 11 64.70% 6 35.30% 17 100% 
lcSSc 13 86.67% 2 13.33% 15 100% 
 
64.70% of dcSSc patients and 86.67% of lcSSc patients had ILD 
and the „P‟ value for this association is 0.1524 which means there is no 
statistically significant association between the subtypes of the disease 
and the development of ILD. 
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 TABLE 21: CARDIOVASCULAR PARAMETERS 
PARAMETER 
dcSSc lcSSc 
RANGE MEAN SD RANGE MEAN SD 
PULSE 68 - 108 87 9.5 70 – 120 89 15 
SYSTOLIC BP 90 - 220 116 29 200 – 90 117 25 
DIASTOLIC BP 60 - 140 75 18 70 – 90 74 7.4 
LVEF% 45 - 63 56.6 5.78 48 – 70 57.9 6.62 
  
In dcSSc subset of patients only one patient had systemic 
hypertension and she was admitted in the hospital with renal crisis. One 
patient in the lcSSc subset also had systemic hypertension and she had 
concomitant chronic kidney disease. 
 
 
 
 
 
 
 TABLE 22: ECG CHANGES 
PARAMETER 
dcSSc-
TOTAL 17 
lcSSc-
TOTAL15 
TOTAL 
NO. % NO. % NO. % 
Axis 
Normal 12 70.59% 11 73.33% 23 71.86% 
RAD 4 23.53% 2 13.33% 6 18.75% 
LAD 1 5.88% 2 13.33% 3 9.38% 
Arrhythmia 0 0% 0 0% 0 0% 
CAD 0 0% 0 0% 0 0% 
Conduction 
Block 
RBBB 1 5.88% 0 0% 1 3.13% 
LBBB 0 0% 0 0% 0 0% 
LAHB 1 5.88% 1 6.67% 2 6.25% 
LPHB 1 5.88% 1 6.67% 2 6.25% 
RBBB+LAHB 0 0% 1 6.67% 1 3.13% 
None 14 82.35% 12 80% 26 81.25% 
In the study population 23 patients (71.86%) had normal axis on 
ECG. 6 patients (18.75%) had right axis deviation of which 4 are dcSSc 
patients and 2 are lcSSc patients.  3 patients (9.38%) had left axis 
deviation. None of the patients showed arrhythmia or abnormal Q waves 
in ECG from both the subset of disease. 1 patient from the dcSSc subset 
had RBBB. None had LBBB. 2 patients (6.25%), one from each subset 
had LAHB. Another 2 patients (6.25%), one from each subset had LPHB. 
1 patient from the lcSSc subset had RBBB+LAHB. 
 TABLE 23: ECHO FINDINGS 
PARAMETER 
dcSSc – Total 17 lcSSc – Total 15 TOTAL – 32 
Number % Number % Number % 
Diastolic 
Dysfunction 
7 41.18% 4 26.67% 11 34.38% 
Motion 
abnormalities 
4 23.53% 3 20% 7 21.86% 
Pericardial 
effusion 
1 5.88% 1 6.67% 2 6.25% 
Pulmonary 
Hypertension 
3 17.65% 2 13.33% 5 15.63% 
Thick 
Pericardium 
3 17.65% 1 6.67% 4 12.5% 
 
11 out of 32 (34.38%) patients had diastolic dysfunction, 7 in the 
dcSSc and 4 in the lcSSc subsets. 7 patients (21.86%) showed motion 
abnormalities in the form of paradoxical septal motion and hypokinesia.  
2 patients (6.25%) had pericardial effusion, one patient from each subset. 
5 patients(15.63%) had pulmonary artery hypertension of which 3 
patients had dcSSc and 2 patients had lcSSc. 4 patients in the study group 
(12.5%) had thick pericardium. 
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 DISCUSSION 
Systemic sclerosis (SSc) is a connective tissue disorder of 
unknown etiology, with heterogeneous clinical manifestations, and 
chronic and often progressive course, which affects the connective tissue 
of the skin, internal organs and the walls of blood vessels. Virtually it 
affects all the organ system of the body. A variety of pulmonary and 
cardiovascular manifestations are associated with systemic sclerosis and 
these are the major cause of morbidity and mortality in these patients.  
In our study we selected 32 patients with systemic sclerosis from 
various IP & OP departments of Govt. Rajaji  Hospital. Madurai. These 
patients were fulfilled the American College of Rheumatology criteria for 
the diagnosis of systemic sclerosis. 
In this study the disease predominantly affects females. The female 
to male ratio in this study population is 4.33:1. According to Davidson‟s 
principles and practice of medicine there is a 4:1 female preponderance 
(23). In a study conducted by Haustein et al the overall female/male ratio 
was reported as 3:1.(3,24)  
In this study the average age of patients is 39.28 years. 58.38% of 
the study population comes under the age group of 30-49 years. 
According to Harrison‟s principle of internal medicine (2) the most 
 common age of onset of this disease is in the range of 30-50 years. In 
Poormoghim et al study the average age was 40.9 years(25). 
The mean duration of the disease is 3.16±2.11 years in our study 
population.  65.62% patients had the symptoms for a period of 1-3 years. 
According to Vinod K Sharma et al (26) the mean duration of the disease 
is 6.49 ± 4.34 years.  
In this study 53.12% of the study population had diffuse cutaneous 
systemic sclerosis and the rest 46.88% had limited cutaneous systemic 
sclerosis. According to LeRoy et al more than 50 % of SSc patients 
belong to the limited SSc(11). 
In the study 52.94% of dcSSc patients and 73.33% of lcSSc 
patients had history of  Raynaud‟s phenomenon and a total of 62.5% of 
the study population had the same. But most of the literature describes a 
prevalence of >90% of Raynaud‟s phenomenon in patients with SSc. 
According to Haustein et al(3)  Raynaud‟s phenomenon  is seen in 98 % 
of SSc patients and it is a forerunner  of SSc. In the AIIMS study by 
Vinod K Sharma et al (26) the prevalence of Raynaud‟s phenomenon was 
92.2%.  Most of my patients in the study population were dark coloured. 
It may be the reason why a low proportion of the study population had 
this phenomenon comparing to the literature.  
 The most common symptom of the patients in the study group was 
difficulty in opening mouth (90.63%). The most common 
cardiorespiratory symptom in the study population was dyspnoea 
(84.38%) followed by dry cough (50%). According to Baron et al(27) up 
to 50% of patients with systemic sclerosis (SSc) have complaints of 
dyspnoea.  In an Indian study done in AIIMS, 55.5% patients had 
restriction of mouth opening and 51.1% patients had  dyspnea(26).  
All patients in the study population had pitted scar at the finger tip 
and sclerodactily. 84.38% had salt and pepper lesions and 93.76% 
patients had microstomia. The most common respiratory finging was 
Velcro crackles(50%).  
The mean duration of the disease in the study group was 3.16±2.11 
years.  According to Terry et al(27) the mean duration is 2.48±1.68 years. 
The mean haemoglobin of the patients was 10.2±1.5g/dl and the mean 
ESR was 38±22.2mm/1
st
 hr. The Modified Rodnan Skin Score of patients 
in the study population was 17.8±5.7.  According to Terry et al(27) the 
mean  Modified Rodnan Skin Score  was 15.1 ± 12.0. According to 
Vinod K Sharma et al (26) the mean Rodnan score was 25.81 +/- 10.04.  
84.38% of the study population showed ANA positivity. According 
to Terry et al the ANA positivity is 94% (27).  According io Cleveland 
 clinic antinuclear antibody (ANA) is positive in 60% to 80% of patients 
with scleroderma (28). In the AIIMS study by Vinod K Sharma et al (26) 
ANA was positive in 89.1% patients(26). Scl 70 antibody was positive in 
35.29% of dcSSc patients in the study population and anti centromere 
antibody was positive in 40% of lcSSc patients in the study group. 
According to Haustein et al (3) Scl 70 antibody is present in 21 – 40% of 
patients with dcSSc and anti entromere antibody is present in 40 – 57% 
patients with lcSSc. 
In the study population 62.5% of patients had abnormal chest x-ray 
findings, 75% of patients had abnormal HRCT finding and 75% patients 
had abnormal PFT findings.  In a study conducted by Totanarungroj et, 
they detected abnormal chest x-ray in 90% patients with SSc and 
abnormal HRCT in 100% patients with SSc. According to Seely et al (30) 
73% patients had abnormal HRCT finding.  
The most common HRCT finding in the study population were 
ground glass opacity (68.75%),interlobar septal thickening(59.38% ) and 
honey combing(56.25%).  According to Totanarungroj et al (29), the 
most common finding was interlobar septal thickening (85%% )  
followed by traction bronchiectasis (75%) and honey combing(40%). In 
their study the ground glass opacity was found in 25% patients.   
 75% of the study population had abnormal pulmonary function 
test. In a study conducted at AIIMS (26) the prevalence of abnormal PFT 
in systemic sclerosis patient was 85.8% and according to Krishnamoorthy 
et al who conducted similar study in south India it is 55% (31). 
In our study among the patients with restrictive PFT 27.27% had 
mild restriction, 45.45% had moderate restriction and the rest 27,27% had 
severe restriction. According to Virginia D et al (32) 27% had moderate 
restriction and 13% had severe restriction. 
The prevalence of ILD in our study population was 75%. 
According to Winklehner (35) et al it is 55%. According to Richard et al 
(36) ~90% % of SSc patients have been found to have pulmonary 
interstitial fibrotic changes at postmortem examination or on high-
resolution computed tomography (HRCT) of the chest, only ~40% 
develop moderate or severe restrictive pulmonary disease on physiologic 
pulmonary function testing (forced vital capacity [FVC] of  ≤75% of 
predicted). According to Harrison‟s principles of internal medicine 
clinically significant ILD develops in 16–43% of patients with SSc and 
some evidence of ILD can be found in up to 90% of patients with SSc at 
autopsy and 85% by thin-section high-resolution computed tomography 
(HRCT). 
 In our study there is no significant association between ILD and 
subtype of systemic sclerosis. 64.70% of dcSSc patients and 86.67% of 
lcSSc patients had ILD in the study population. 
In dcSSc patients who were affected by ILD there is a significant 
association with sex, MRSS and PFT findings. Female sex and patients 
with MRSS score >17 are having statistically significant more chance for 
the development of ILD. But there is no significant association with 
duration of disease or antibody profile to the development of ILD in this 
subset of patients. In lcSSc subset of patients there is no statistically 
significant association with development of ILD and duration of disease, 
MRSS >12, & antibody profile.   
In the study population 28.14% patients had axis deviation in ECG. 
None of the patients had arrhythmias or ischemic changes in ECG. 
18.75% of patients had some degree of conduction block, of which 
LAHB and LPHB predominates (6.25% each). According to 
Poormoghim et al (25) the prevalence of abnormal axis in ECG is 10.3%, 
arrhythmia 3.5%, ischemic changes 1.7% and conduction block 13.8%.  
34.38% of the patients had diastolic dysfunction. 21.86% patients 
had some degree of motion abnormalities. 6.25% patients had pericardial 
effusion and 12.5% patients had thick parietal pericardim. According to 
 Tünde Pintér et al(38) the prevalence of diastolic dysfunction is 79.2% in 
patients with systemic sclerosis. In Poormoghim et al (25) study 15.4% of 
patients had pericardial effusion. In the Janosik et al (37) study, 
pathological involvement of  the pericardium was observed in 70%-80% 
of the patients at  autopsy, while clinical manifestation was present in 
7%-20%  of the study subjects. They reported an association between  
pericardial effusion and cardiac involvement; pericardial  effusions were 
small or large and had developed rapidly in  some cases due to renal 
failure. In our study one patient with pericardial effusion had acute renal 
crisis. In Fischer et al (40) study 49% 0f patients with systemic sclerosis 
had a thick pericardium.  
15.63% patients had pulmonary hypertension (17.65% of dcSSc 
patients and 13.33% of lcSSc patients).  All of the patients with 
pulmonary hypertension had associated ILD also. None of the patients in 
the study population had isolated pulmonary hypertension. According to 
Robyn et al (39) the incidence of PAH related to SSc ranges from 4% to 
35%, with slightly more PAH cases associated with lcSSc than with 
dcSSc. In some series, 50% to 90% of SSc patients with PAH had lcSSc, 
whereas 8% to 50% had dcSSc. Others have reported 13% to 50% of 
lcSSc patients develop PAH. The prevalence of PAH related to SSc 
correlates with the underlying systemic disease, ie, more often in women 
 35 to 55 years of age. According to  Harrison‟s principles of internal 
medicine approximately 15% of SSc patients have PAH that can occur in 
association with ILD or as an isolated pulmonary abnormality. According 
to Diotet al incidence of PAH is 15–35% in patients with limited 
cutaneous SSc, usually as isolated PAH, and 30% in patients with diffuse 
cutaneous SSc, frequently associated with pulmonary fibrosis (41). 
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSIONS 
1.  Sex ratio of male to female in this study is 1:4.33 
2.  Most patients are distributed under the age group 40 – 49 years 
3.  65.62% patients had the symptoms for a period of 1-3 years only. 
4.  53.12% had dcSSc and 46.88% had lcSSc subsets of disease. 
5.  Patients with Raynaud‟s phenomenon are 62.5%. 
6.  Restricted mouth opening is the most common symptom and 
dyspnoea on excertion is the most common cardiopulmonary 
symptom 
7.  All patients had digital stellate scar and sclerodactyly. 
8.  ANA is positive in 84.38% of patients. Scl 70 antibody is positive in 
35.29% of patients with dcSSc and anticentromere antibody is 
positive in 40% of patients with lcSSc 
9.  68.25% patients had restrictive lung disease in PFT. 
10.  The most common pulmonary manifestation is ILD in the study 
group. 75% of the studied population had ILD. 
11.  34.38% patients had diastolic dysfunction, 6.25% patients had 
pericardial effusion and 15.63% patients had pulmonary 
hypertension. 
 
 
  
LIMITATIONS 
 
1.  The study group contains 32 patients only. 
2.  Investigations like diffusion study, cardiac catheterization and 
broncho alveolar lavage could not be done. 
3.  No male patients were there with lcSSc. 
 
 
 
 
 
 
 
 
 
 
 
 
 SUMMARY 
 The study „Cardiopulmonary Manifestations of Systemic Sclerosis‟ is 
a descriptive study conducted on patients with systemic sclerosis who were 
treated in Govt. Rajaji Hospital, Madurai. Thirty two patients were included 
in the study and were investigated to detect the presence of various cardiac 
and pulmonary manifestations of systemic sclerosis.  
 Analyzing the data shows a female preponderance of the disease in 
the study population with a female to male ratio of 4.33:1. Diffuse 
cutaneous subtype of the disease is more in number than the limited 
cutaneous subtype. Dyspnoea was the most common cardiopulmonary 
symptom. 62.5% of the patients had Raynaud‟s phenomenon. ILD was the 
most common pulmonary manifestation with a prevalence of 75%. 6.25% 
patients had pleural effusion. 34.38% patients had diastolic dysfunction and 
6.25% patients had pericardial effusion. 15.63% of them had pulmonary 
artery hypertension and all of them are associated with interstitial lung 
disease.  
 
 
 
                                                      GLOSSARY 
 
SSc                  -         Systemic Sclerosis 
dcSSc    -     Diffuse Cutaneous Systemic Sclerosis 
lcSSc              -          Limited Cutaneous Systemic Sclerosis  
ESR                -         Erythrocyte sedimentation rate  
Hb                   -         Hemoglobin 
MRSS             -         Modified Rodnan Skin Score  
PFT                 -         Pulmonary function test 
HRCT             -         High resolution computed tomography 
FVC                -         Forced vital capacity 
FEV1              -         Forced expiratory volume in first one second 
FEF                -          Forced expiratory flow 
ILD                -          Interstitial lung disease 
IPF                 -          Idiopathic pulmonary fibrosis 
Scl-70   -    Anti topoisomerase 1 antibody 
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 PROFORMA 
CARDIO PULMONARY MANIFESTATIONS OF SYSTEMIC 
SCLEROSIS 
Name:                                                                        Age:            Sex:                 
IP No: 
Address:                                                                                                                
Phone No: 
Clinical features: 
Raynaud‟s phenomenon                                                  Dyspnoea 
Arthritis                                                                            Palpitation                             
Muscle weakness                                                             Chest pain    
Dry mouth                                                                        Syncope  
Dry eyes                                                                           Dry cough 
Difficulty in opening mouth                                             Haemoptysis     
                GER                                                                                 Dysphagia 
 
Past History 
HTN/DM/TB/BA/ATT/CAD/COPD/RHD/Pneumothorax 
Personal History 
Smoking 
Family History 
HTN/DM/CAD/TB/BA 
 
 
 
  
VITALS 
PR: 
BP:                                                                                 RR: 
GENRAL EXAMINATION 
Pallor:                                                                         Cyanosis: 
Clubbing:                                                                    Pedal oedema: 
DERMATOLOGICAL 
Hyper pigmentation:                                                   Calcinosis cutis: 
Telengectasia:                                                              Pitted scars on pulp 
of fingers: 
Salt & Pepper lesions:                                                 Microstomia: 
Skin ulcers:                                                                  Skin thickening:    
 
CVS                                                                        Musculoskeletal 
System   
JVP                                                                         Carpel Tunnel 
Syndrome:  
LVH                                                                 Flexon  contractures of 
fingers 
Heart sounds                                                    Sclerodactily                                                            
Murmurs                                                           Tendon Friction Rubs        
RS                                                                      Others 
Velcro Rales: 
Added sounds: 
 Pleural effusion: 
 
INVESTIGATIONS 
 
Hb:                                                  RBS:                                  ANA: 
TC:                                                  UREA:                               Scl 70:    
DC:                                                  CREATININE:                
Anticentromere  
ESR:                                                                                                   
Platelet Count:                                                                               
Peripheral smear:                                                                                                                                                                                                              
ECG: 
 
ECHO: 
 
 
CXR: 
 
HRCT: 
 
 
 
PFT: 
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1 Akhila 32 F 7 Y Y N Y Y Y Y Y N N N N 92 110 70 28 N Y 28
2 Chellapandi 24 M 1 Y Y N Y Y N Y Y Y N N N 84 100 70 22 N Y 31
3 Meena 45 F 1 Y N N Y N N Y N N N N N 108 100 60 20 N Y 32
4 Mariyammal 40 F 1 Y Y N Y Y Y Y N N N N N 70 90 70 24 N Y 12
5 Sathish Kumar 20 M 1 N N N Y N N N N N N N N 84 110 70 18 N Y 14
6 Nagajyothi 40 F 7 Y Y Y Y Y Y Y Y N Y Y N 90 110 70 22 N Y 12
7 Alamelu 43 F 3 N Y N Y Y N Y N N Y N N 92 110 70 26 N Y 30
8 Seeniyamal 50 F 2 Y Y N Y Y Y Y Y N Y N Y 76 200 90 20 N Y 14
9 Kavitha 30 F 3 Y Y N Y Y Y Y N N N N N 86 110 70 16 N Y 16
10 Suganthini 31 F 7 Y Y Y Y Y Y Y Y N N N N 120 100 70 32 N Y 18
11 Gayathri 20 F 3 Y Y N Y N N Y N N N N N 76 110 70 20 N Y 12
12 Pothumani 35 F 5 Y N Y Y Y Y Y Y N N N N 108 120 70 44 N Y 12
13 Balamurugan 29 M 2 N Y N N Y Y Y N N N N N 86 90 60 20 N Y 21
14 Kanakavally 40 F 2 N Y Y Y Y Y N Y N Y N N 90 104 70 16 N Y 14
15 Malathy 51 F 1 N N N Y Y Y Y Y N N Y N 110 110 70 40 N Y 13
16 Vellaiyammal 47 F 1 N Y Y Y Y Y Y N N Y Y N 90 220 140 30 N Y 16
17 Rajangam 55 M 2 N N N Y Y N N N N N N N 96 110 70 34 N Y 17
18 Malar 35 F 5 Y N Y Y Y Y Y Y N Y Y Y 78 120 80 22 N Y 12
19 Lakshmi 55 F 1 N N N N Y N Y N N N Y N 80 120 80 18 N Y 18
20 Muniyammal 56 F 4 N Y N Y Y N Y N N Y Y N 90 100 70 18 N Y 16
21 Mehraj Beeegum 28 F 8 Y Y N Y N Y Y N N N Y N 92 110 70 24 N Y 17
22 Vasantha 40 F 2 Y Y N Y Y N Y Y N N Y N 84 130 90 18 N Y 18
23 Mariyammal 50 F 1 N Y Y Y Y N Y N N N N N 96 90 60 22 N Y 18
24 Anandi 35 F 1 N Y Y Y Y Y Y N N Y N N 96 126 80 26 N Y 13
25 Selvapandi 28 M 2 Y Y N Y Y Y Y Y N N N N 84 130 80 20 N Y 19
26 Rathinam 58 F 3 Y Y N N Y N N N N N N N 76 110 70 18 N Y 11
27 Janaki 36 F 5 Y Y N Y Y Y Y Y N Y N N 92 120 70 26 N Y 20
28 Fathimuthu 47 F 6 Y N N Y Y Y Y Y N Y N N 68 110 70 20 N Y 22
29 Vijayalakshmi 33 F 4 N N N Y Y Y Y N N N N N 78 120 80 16 N Y 21
30 Duraipandi 45 M 3 Y N Y Y N N N Y N N N N 82 110 70 18 N Y 17
31 Poongodi 30 F 2 Y Y N Y Y Y Y Y N N Y N 70 116 70 24 N Y 16
32 Parameswari 49 F 5 Y Y Y Y Y Y Y Y N N Y N 96 110 80 28 N Y 22
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N N N N N Y N Y Y N N Y Y N N N Y N 11 32 67 0.8 P N N N
N Y N N N Y N Y Y N N Y Y N N N N N 11 46 103 1.2 N P N Y
N N Y Y Y N N Y Y N N Y Y N N N N N 10 55 118 1.6 P N P Y
N N N N N Y N Y Y N N Y Y N N N N N 12.2 25 70 0.7 N P N N
N N N N N Y N Y Y N N Y Y N N N N N 11 12 75 0.8 P N N Y
N Y Y N Y Y Y Y Y N N Y Y N N N N N 9.7 88 98 0.8 P N N Y
N N Y N Y Y N Y Y N N Y Y N N N N N 8.2 42 64 2.1 P N P Y
N N Y N N N N Y Y N N Y Y N N N N N 9.5 35 92 0.8 P N N N
N Y Y N Y Y N Y Y N N Y Y N N N Y N 11.8 12 104 0.8 N N N Y
N N N N N N N Y Y N N Y Y N N N N N 9.2 52 133 0.8 P P N N
Y Y Y Y N N Y Y Y N N Y Y N N N N N 14.2 9 156 0.8 N N N Y
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V
O
L.
LO
SS
p
l.e
ff
u
si
o
n
 
ca
rd
io
m
eg
al
y
C
T
C
T-
gr
o
u
n
d
 
gl
as
s
re
ti
 n
o
d
H
o
n
ey
 C
o
m
b
M
e
d
 L
N
IL
ST
N
o
d
u
le
s
b
ro
ec
ta
si
s
p
er
ib
ro
 t
h
p
l e
ff
n
p
l t
h
ic
kn
P
FT
FV
C
FE
V
1
FV
C
 %
FE
V
1
 %
FE
V
1
/F
V
C
P
FT
EC
H
O
Y N N Y N Y N Y Y Y N N Y 1.24 1.15 59 62 93 M.RESTRICTION
Y N N N N Y N Y Y Y N N N 1.29 1.06 34 32 82.2 S.RESTRICTION Alt,Sept,mot
Y N N Y Y Y N Y N Y N N Y 1.18 1.07 47 42 90.7 S.RESTRICTION NORMAL
N N N Y Y N N Y Y Y N N N 1.66 1.55 52 56 93.4 M.RESTRICTION NORMAL
N N N N N N N N N N N N N 4.41 4.17 103 114 94.6 NORMAL NORMAL
N N N Y Y Y N Y N N N N N 1.5 1.35 69 74 90 M.RESTRICTION NORMAL
Y N N Y Y Y N Y N Y N N N 1.02 1.02 40 47 100 S.RESTRICTION NORMAL
N N N Y N N N Y N N N N Y 1.22 1.12 74 78 92 M.RESTRICTION
N N N N N N N N N N N N N 1.91 1.83 60 76 95 M.RESTRICTION NORMAL
N N N Y Y Y N Y Y N N N N 1.34 1.21 68 75 90 M.RESTRICTION
N N N N N N N N N N N N N 2.21 1.78 96 92 81 NORMAL NORMAL
N Y N Y Y Y Y Y N Y N Y Y 1.84 1.68 71 82 91 M.RESTRICTION
N N N N N N N N N N N N N 2.58 0.38 74 12 14.7 S.OBSTRUCTION NORMAL
Y N N N N N N N N N N N N 1.87 1.8 72 81 96.3 M.RESTRICTION NORMAL
Y N N Y N Y N N N Y N N N 0.87 0.85 41 47 97.7 S.RESTRICTION
N N Y Y N N N N N N N Y N 1.97 1.68 88 82 85 NORMAL
N N N N N N N N N N N N N 2.34 1.87 82 84 80 NORMAL
N N N N Y N N Y Y Y N N Y 1.13 1.13 66 81 100 M.RESTRICTION NORMAL
N N N N N N N N N N N N N 1.66 1.46 86 90 87.9 NORMAL NORMAL
N N N Y Y N N Y Y N N N Y 1.56 1.42 70 76 91 M.RESTRICTION NORMAL
Y N N Y N Y N Y Y Y N N Y 0.97 0.87 35 37 89.7 S.RESTRICTION
Y N N Y Y Y N Y Y Y N N Y 1.5 1.44 47 53 96 S.RESTRICTION
N N N Y N Y N Y N Y N N Y 1.14 0.55 43 24 48.2 S.OBSTRUCTION
N N N N N N N N N N N N N 1.94 1.82 75 81 93.8 NORMAL NORMAL
Y N N Y Y Y N Y Y Y N N Y 1.66 1.36 69 68 82 M.RESTRICTION NORMAL
N N N Y N N N N N N N N N 2.74 2.34 92 89 85 NORMAL NORMAL
Y N N Y Y Y N Y Y Y N N Y 1.31 1.12 67 69 86 M.RESTRICTION
N N N Y N Y Y Y N Y N N Y 1.42 1.23 72 76 86 M.RESTRICTION
N N N Y N Y Y N Y N N N Y 1.33 1.24 59 70 93 M.RESTRICTION NORMAL
N N N N N N N N N N N N N 2.45 2.24 85 97 91 NORMAL NORMAL
Y N N Y Y Y N Y N Y N N Y 1.96 1.84 68 79 94 M.RESTRICTION NORMAL
Y N N Y Y Y N Y Y Y N N Y 1.63 1.42 57 62 88 M.RESTRICTION
LV
EF
D
IA
S.
D
YS
F
P
A
H
P
SM
V
.P
ER
IC
A
D
P
ER
I.
EF
U
C
H
EM
B
ER
A
X
IS
C
A
D
A
R
R
YT
H
M
IA
SE
P
T.
IN
FA
R
H
EA
R
T 
B
LO
C
K
51 Y Y Y THICK N RVH RAD N N N N
53 N N N NORMAL N NORMAL RAD N N N N
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61 N N N NORMAL N NORMAL NORMAL N N N N
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